Cardiex is an Australian health tech company reshaping how cardiovascular health is measured and managed. At its core is SphygmoCor, a clinically validated technology that captures advanced arterial biomarkers like central blood pressure, pulse wave velocity, and arterial stiffness—insights traditionally only available in specialty clinics. In professional settings, their XCEL and Oscar 2 devices are widely used in research institutions, hospitals, and pharmaceutical trials.

For consumers, the FDA-cleared CONNEQT Pulse brings those same hospital-grade insights into the home, and the company is pairing this with a multi-tier subscription app that delivers personalized cardiovascular feedback. But the bigger vision is what comes next.

Looking ahead, Cardiex is evolving into a health data platform. Its upcoming SphygmoCloud service will offer vascular analytics as a cloud-based API, allowing device makers—from wearables to hospital monitors—to feed in raw arterial signals and receive advanced biomarker insights in return. This shifts Cardiex from a hardware company to an engine for vascular intelligence across the digital health ecosystem.